Compare the Performance of Targeted Biopsy Versus Aspiration Biopsy With a Pipette for the Diagnosis of Endometrial Cancer

• Register: ClinicalTrials.gov
• Last refreshed on: 12 December 2020
• Main ID: NCT03115593
• Date of registration: 11/04/2017
• Prospective Registration: Yes
• Primary sponsor: Brugmann University Hospital
• Public title: Compare the Performance of Targeted Biopsy Versus Aspiration Biopsy With a Pipette for the Diagnosis of Endometrial Cancer
• Scientific title: Compare the Performance of Targeted Biopsy Versus Aspiration Biopsy With a Pipette for the Diagnosis of Endometrial Cancer
• Date of first enrolment: July 10, 2018
• Target sample size: 0
• Recruitment status: Withdrawn
• URL: https://clinicaltrials.gov/show/NCT03115593
• Study type: Interventional
• Study design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Diagnostic. Masking: None (Open Label).
• Phase: N/A

Countries of recruitment

Belgium, France

Contacts

• Name: André Nazac, MD
• Affiliation: CHU Brugmann

Key inclusion & exclusion criteria

Inclusion Criteria:

- postmenopausal patient.

- patient with postmenopausal metrorrhagia and endometrial hypertrophy defined by an
endometrium ticker than 3 mm (ultrasound result)

Exclusion Criteria:

- patients undergoing hormone replacement therapy for menopause (THM). This treatment
may be the cause of benign bleeding in post menopause.



Age minimum: N/A
Age maximum: N/A
Gender: Female

Health Condition(s) or Problem(s) studied

Endometrial Cancer

Intervention(s)

Procedure: Blind biopsy with a pipette

Procedure: Targeted biopsy using hysteroscopy

Primary Outcome(s)

Histological result [Time Frame: 6 months]

Secondary ID(s)

CHUB-Hystocor

Source(s) of Monetary Support

Please refer to primary and secondary sponsors